Director

Reshema Kemps-Polanco

Director (Executive Vice President and Chief Commercial Officer, Novartis US)·Charles River Laboratories International, Inc.

About

R

e

s

h

e

m

a

K

e

m

p

s

-

P

o

l

a

n

c

o

i

s

E

x

e

c

u

t

i

v

e

V

i

c

e

P

r

e

s

i

d

e

n

t

a

n

d

C

h

i

e

f

C

o

m

m

e

r

c

i

a

l

O

f

f

i

c

e

r

o

f

N

o

v

a

r

t

i

s

U

S

,

t

h

e

U

.

S

.

o

p

e

r

a

t

i

o

n

s

o

f

g

l

o

b

a

l

b

i

o

p

h

a

r

m

a

c

e

u

t

i

c

a

l

c

o

m

p

a

n

y

N

o

v

a

r

t

i

s

A

G

,

w

h

e

r

e

s

h

e

i

s

r

e

s

p

o

n

s

i

b

l

e

f

o

r

e

n

d

-

t

o

-

e

n

d

c

o

m

m

e

r

c

i

a

l

i

z

a

t

i

o

n

a

c

r

o

s

s

f

o

u

r

t

h

e

r

a

p

e

u

t

i

c

a

r

e

a

s

,

i

n

c

l

u

d

i

n

g

o

n

c

o

l

o

g

y

,

i

m

m

u

n

o

l

o

g

y

,

n

e

u

r

o

l

o

g

y

,

a

n

d

c

a

r

d

i

o

v

a

s

c

u

l

a

r

/

r

e

n

a

l

/

m

e

t

a

b

o

l

i

c

c

o

n

d

i

t

i

o

n

s

.

M

s

.

K

e

m

p

s

-

P

o

l

a

n

c

o

r

e

t

u

r

n

e

d

t

o

N

o

v

a

r

t

i

s

i

n

2

0

2

1

a

s

E

V

P

&

U

S

H

e

a

d

,

N

o

v

a

r

t

i

s

O

n

c

o

l

o

g

y

.

P

r

i

o

r

t

o

r

e

j

o

i

n

i

n

g

N

o

v

a

r

t

i

s

,

s

h

e

h

e

l

d

s

e

v

e

r

a

l

l

e

a

d

e

r

s

h

i

p

p

o

s

i

t

i

o

n

s

a

t

J

o

h

n

s

o

n

&

J

o

h

n

s

o

n

f

r

o

m

2

0

1

4

u

n

t

i

l

2

0

2

1

,

m

o

s

t

r

e

c

e

n

t

l

y

a

s

P

r

e

s

i

d

e

n

t

,

J

a

n

s

s

e

n

U

.

S

.

C

a

r

d

i

o

v

a

s

c

u

l

a

r

&

M

e

t

a

b

o

l

i

s

m

a

n

d

J

a

n

s

s

e

n

P

h

a

r

m

a

c

e

u

t

i

c

a

l

s

P

u

e

r

t

o

R

i

c

o

,

w

h

e

r

e

s

h

e

w

a

s

r

e

s

p

o

n

s

i

b

l

e

f

o

r

d

e

v

e

l

o

p

i

n

g

a

n

d

d

e

l

i

v

e

r

i

n

g

t

h

e

b

u

s

i

n

e

s

s

s

t

r

a

t

e

g

y

a

n

d

d

r

i

v

i

n

g

g

r

o

w

t

h

i

n

i

t

i

a

t

i

v

e

s

f

o

r

t

h

o

s

e

b

u

s

i

n

e

s

s

e

s

.

M

s

.

K

e

m

p

s

-

P

o

l

a

n

c

o

b

e

g

a

n

h

e

r

p

h

a

r

m

a

c

e

u

t

i

c

a

l

i

n

d

u

s

t

r

y

c

a

r

e

e

r

a

t

N

o

v

a

r

t

i

s

i

n

2

0

1

2

i

n

s

a

l

e

s

a

n

d

h

e

l

d

m

a

n

a

g

e

m

e

n

t

p

o

s

i

t

i

o

n

s

o

f

i

n

c

r

e

a

s

i

n

g

r

e

s

p

o

n

s

i

b

i

l

i

t

y

,

i

n

c

l

u

d

i

n

g

l

e

a

d

i

n

g

t

h

e

U

.

S

.

c

o

m

m

e

r

c

i

a

l

t

e

a

m

'

s

m

a

r

k

e

t

i

n

g

s

t

r

a

t

e

g

y

f

o

r

i

t

s

l

e

u

k

e

m

i

a

f

r

a

n

c

h

i

s

e

a

n

d

s

e

r

v

i

n

g

a

s

U

.

S

.

b

r

a

n

d

l

e

a

d

e

r

f

o

r

i

t

s

o

s

t

e

o

p

o

r

o

s

i

s

t

h

e

r

a

p

y

.

S

h

e

i

s

a

m

e

m

b

e

r

o

f

t

h

e

R

u

t

g

e

r

s

C

a

n

c

e

r

I

n

s

t

i

t

u

t

e

L

e

a

d

e

r

s

h

i

p

C

o

u

n

c

i

l

,

t

h

e

H

e

a

l

t

h

c

a

r

e

B

u

s

i

n

e

s

s

w

o

m

e

n

'

s

A

s

s

o

c

i

a

t

i

o

n

(

H

B

A

)

G

l

o

b

a

l

A

d

v

i

s

o

r

y

B

o

a

r

d

,

a

n

d

t

h

e

C

E

O

R

o

u

n

d

t

a

b

l

e

o

n

C

a

n

c

e

r

.

M

s

.

K

e

m

p

s

-

P

o

l

a

n

c

o

h

a

s

b

e

e

n

a

d

i

r

e

c

t

o

r

o

f

C

h

a

r

l

e

s

R

i

v

e

r

s

i

n

c

e

J

a

n

u

a

r

y

2

0

2

4

.

S

h

e

w

a

s

s

e

l

e

c

t

e

d

f

o

r

t

h

e

B

o

a

r

d

i

n

r

e

c

o

g

n

i

t

i

o

n

o

f

h

e

r

e

x

t

e

n

s

i

v

e

h

e

a

l

t

h

c

a

r

e

b

u

s

i

n

e

s

s

l

e

a

d

e

r

s

h

i

p

k

n

o

w

l

e

d

g

e

,

d

e

e

p

i

n

d

u

s

t

r

y

e

x

p

e

r

i

e

n

c

e

a

t

t

w

o

o

f

t

h

e

t

o

p

-

1

0

g

l

o

b

a

l

p

h

a

r

m

a

c

e

u

t

i

c

a

l

c

o

m

p

a

n

i

e

s

,

h

e

r

d

e

m

o

n

s

t

r

a

t

e

d

a

b

i

l

i

t

y

t

o

o

v

e

r

s

e

e

l

a

r

g

e

c

o

m

m

e

r

c

i

a

l

o

r

g

a

n

i

z

a

t

i

o

n

s

a

c

r

o

s

s

m

u

l

t

i

p

l

e

t

h

e

r

a

p

e

u

t

i

c

a

r

e

a

s

,

a

n

d

h

e

r

o

v

e

r

2

5

y

e

a

r

s

o

f

e

x

p

e

r

i

e

n

c

e

i

n

t

h

e

l

i

f

e

-

s

c

i

e

n

c

e

s

s

e

c

t

o

r

.

Since January 2024
Age 53
Tenure 2 yrs

Also at Charles River Laboratories International, Inc.

JF James C. Foster Chair, President and Chief Executive Officer BG Birgit Girshick Corporate Executive Vice President and Chief Operating Officer (Chief Executive Officer effective May 5, 2026) NA Nancy C. Andrews Director (Executive Vice President and Chief Scientific Officer, Boston Children's Hospital) SB Steven Barg Director (Global Co-Head of Engagement, Elliott Investment Management L.P.) AC Abraham Ceesay Director (Chief Executive Officer, Rapport Therapeutics) ME Mark Enyedy Director (Former President and Chief Executive Officer, ImmunoGen, Inc.)

Roles

Organization Role Dates Details
Charles River Laboratories International, Inc. Director (Executive Vice President and Chief Commercial Officer, Novartis US) January 2024–present Current role
Novartis US Executive Vice President and Chief Commercial Officer present Returned to Novartis in 2021 as EVP & US Head, Novartis Oncology.
Johnson & Johnson Several leadership positions, most recently President, Janssen U.S. Cardiovascular & Metabolism and Janssen Pharmaceuticals Puerto Rico 2014 - 2021
Novartis Sales and management positions of increasing responsibility Began 2012 Led the U.S. commercial team's marketing strategy for its leukemia franchise and served as U.S. brand leader for its osteoporosis therapy.
Johnson & Johnson (Janssen) President, US Cardiovascular & Metabolism Unit

External roles

Organization Role Dates
Novartis US Executive Vice President and Chief Commercial Officer present
Rutgers Cancer Institute Leadership Council Member
Healthcare Businesswomen's Association (HBA) Global Advisory Board Member
CEO Roundtable on Cancer Member

Related

Company Charles River Laboratories International, Inc. Company hub Person James C. Foster Chair, President and Chief Executive Officer Person Birgit Girshick Corporate Executive Vice President and Chief Operating Officer (Chief Executive Officer effective May 5, 2026) Person Nancy C. Andrews Director (Executive Vice President and Chief Scientific Officer, Boston Children's Hospital) Person Steven Barg Director (Global Co-Head of Engagement, Elliott Investment Management L.P.) Person Abraham Ceesay Director (Chief Executive Officer, Rapport Therapeutics) Person Mark Enyedy Director (Former President and Chief Executive Officer, ImmunoGen, Inc.) Person Paul Graves Director (Former Chief Executive Officer, Rio Tinto Lithium) Person George Llado, Sr. Director (Former Senior Vice President and Chief Information Officer, Alexion Pharmaceuticals, Inc.) Person Martin W. Mackay Director (Lead Independent Director; Co-Founder and Non-Executive Chair, Rallybio Corporation) Person Craig B. Thompson Director (President Emeritus and Former President and Chief Executive Officer, Memorial Sloan Kettering Cancer Center) Person Virginia M. Wilson Director (Retired Senior Executive Vice President and Chief Financial Officer, TIAA) Person Michael Knell Interim Chief Financial Officer, Corporate Senior Vice President, and Chief Accounting Officer Deal Charles River Laboratories International Agilux Laboratories 2016 Deal page Deal Charles River Laboratories International Argenta And Biofocus Cro Services Division Of Galapagos 2014 Deal page Deal Charles River Laboratories International Blue Stream Laboratories 2016 Deal page
Source: Charles River Laboratories International, Inc. SEC filings and official company website

See how VectorShift works for your firm

Request Demo